Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.

摘要: Both hormone replacement therapy (HRT) and bisphosphonates are efficacious in the prevention treatment of postmenopausal osteoporosis. Combined with bisphosphonate HRT is likely to be used clinical practice, limited data available regarding its efficacy safety. This was a 1-yr, double blind, placebo-controlled study which 524 women received daily conjugated equine estrogens (0.625 mg) alone or combination risedronate (5 mg). Women who had not undergone hysterectomy medroxyprogesterone acetate (up 5 mg, cyclically) at discretion investigator. The primary end point percent change from baseline mean lumbar spine bone mineral density (BMD) 1 yr. Changes BMD proximal femur forearm, turnover markers, histology histomorphometry were also assessed. At 12 months, significant (P < 0.05) increases observed both gr...